+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 1Month - 18Years
All Genders
ID06978439

Pilot Study of Model-Informed Rivaroxaban Dose Adjustment for Chinese Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

Led by Children's Hospital of Fudan University · Updated on 2026-10-22

10

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a 15 mg-equivalent, age- and bodyweight-adjusted dosing regimen of rivaroxaban for Chinese children who have giant coronary artery aneurysms GCAA following Kawasaki disease. This pilot study aims to assess the feasibility of this dosing in a small group of patients, as GCAA is a rare but serious complication of Kawasaki disease that puts children at high risk for coronary artery thrombosis and other cardiovascular events. The study is motivated by previous findings suggesting Asian patients may require lower doses of rivaroxaban and the lack of trials specifically targeting this group. Participants will receive rivaroxaban as an anticoagulant using the proposed 15 mg-equivalent dosing regimen adjusted for age and bodyweight. This dosing strategy is based on a model-informed dose optimization study and aims to provide effective thromboprophylaxis while considering safety concerns such as bleeding risk. The treatment period lasts at least six months, during which participants will be monitored closely. During the study, participants will be followed for over six months to track clinical outcomes like new coronary artery thrombosis, major adverse cardiovascular events, and bleeding episodes. Rivaroxaban blood levels will be measured to evaluate the dosing models reliability. Researchers will also record any dose adjustments and adverse events to assess safety. This thorough follow-up includes clinical assessments and laboratory tests to ensure accurate monitoring of treatment effects and participant well-being.

CONDITIONS

Brief Title

Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease

Research Team

F

Fang Liu, MD

G

Guangan Dai, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here